CNW/ - Takeda Canada Inc. ("Takeda") is pleased to announce that Health Canada has provided market authorization for ...

Takeda Canada said Health Canada has provided market authorization for FRUZAQLA, indicated for the treatment of adult patients with ...

Takeda Canada Inc. ("Takeda") is pleased to announce that Health Canada has provided market authorization for FRUZAQLAtm (fruquintinib capsules), indicated for the treatment of adult patients with ...

Takeda received a national reimbursement recommendation for FRUZAQLA® (fruquintinib) for patients with previously treated metastatic colorectal cancer (“CRC”) in Spain in December 2024 ...

When it comes to the bumper $62bn takeover of UK drugs group Shire by its larger Japanese rival Takeda Pharmaceutical (whose ...

With three internally-discovered medicines marketed in China, it is building on momentum around Fruzaqla, its first cancer drug that broke into developed markets like the US, Europe and Japan via ...

With three internally-discovered medicines marketed in China, it is building on momentum around Fruzaqla, its first cancer drug that broke into developed markets like the US, Europe and Japan via ...

With three internally-discovered medicines marketed in China, it is building on momentum around Fruzaqla, its first cancer drug that broke into developed markets like the US, Europe and Japan via a ...

FRUZAQLA® is the first novel targeted therapy in Japan to be approved for metastatic CRC, regardless of biomarker status, in over a decade. CRC is the most prevalent type of cancer in Japan ...